Hau, Peter and Jachimczak, Piotr and Schlingensiepen, Reimar and Schulmeyer, Frank and Jauch, Tanya and Steinbrecher, Andreas and Brawanski, Alexander and Proescholdt, Martin and Schlaier, Juergen and Buchroithner, Johanna and Pichler, Josef and Wurm, Gabriele and Mehdorn, Maximilian and Strege, Rainer and Schuierer, Gerhard and Villarrubia, Victoria and Fellner, Franz and Jansen, Olav and Straube, Thorsten and Nohria, Virinder and Goldbrunner, Michael and Kunst, Mechthild and Schmaus, Susanne and Stauder, Gerhard and Bogdahn, Ulrich and Schlingensiepen, Karl-Hermann (2007) Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. OLIGONUCLEOTIDES, 17 (2). pp. 201-212. ISSN 1545-4576, 1557-8526
Full text not available from this repository. (Request a copy)Abstract
Transforming growth factor-beta2 (TGF-beta 2) is known to suppress the immune response to cancer cells and plays a pivotal role in tumor progression by regulating key mechanisms including proliferation, metastasis, and angiogenesis. For targeted protein suppression the TGF-beta 2-specific antisense oligodeoxynucleotide AP 12009 was developed. In vitro experiments have been performed to prove specificity and efficacy of the TGF-beta 2 inhibitor AP 12009 employing patient-derived malignant glioma cells as well as peripheral blood mononuclear cells (PBMCs) from patients. Clinically, the antisense compound AP 12009 was assessed in three Phase I/II-studies for the treatment of patients with recurrent or refractory malignant (high-grade) glioma WHO grade III or IV. Although the study was not primarily designed as an efficacy evaluation, prolonged survival compared to literature data and response data were observed, which are very rarely seen in this tumor indication. Two patients experienced long-lasting complete tumor remissions. These results implicate targeted TGF-beta 2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, TGF-beta 2-overexpressing tumors.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-FACTOR-BETA; TUMOR-INDUCED IMMUNOSUPPRESSION; TGF-BETA; BRAIN-TUMORS; ANTISENSE OLIGONUCLEOTIDES; GLIOBLASTOMA; CANCER; CELLS; TEMOZOLOMIDE; EXPRESSION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurochirurgie Medicine > Lehrstuhl für Neurologie Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Jan 2021 10:59 |
| Last Modified: | 13 Jan 2021 10:59 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33495 |
Actions (login required)
 |
View Item |
